Volume 23 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(5): 899-902
CHEN Yang, WEI Junan, FENG Youfan, FU Yuan, CHEN Qiaolin, ZHANG Qike, WEI Xiaofang. Venetoclax combined with azacitidine in treatment of acute myeloid leukemia secondary to multiple myeloma: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2025, 23(5): 899-902. doi: 10.16766/j.cnki.issn.1674-4152.004027
Citation: CHEN Yang, WEI Junan, FENG Youfan, FU Yuan, CHEN Qiaolin, ZHANG Qike, WEI Xiaofang. Venetoclax combined with azacitidine in treatment of acute myeloid leukemia secondary to multiple myeloma: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2025, 23(5): 899-902. doi: 10.16766/j.cnki.issn.1674-4152.004027
shu

Venetoclax combined with azacitidine in treatment of acute myeloid leukemia secondary to multiple myeloma: report of 1 case and review of literature

doi: 10.16766/j.cnki.issn.1674-4152.004027
  • 1.

    Department of Hematology, Gansu Provincial Hospital, Lanzhou, Gansu 730000, China

Funds:

 22JR5RA660

 23GSSYF-333

 GSWSKY2023-78

  • Received Date: 2024-05-08
    Available Online: 2025-08-14
    Abstract
  • We retrospectively analyzed the clinical data of a patient of acute myeloid leukemia secondary to multiple myeloma treated with venetolclax combined with azacidacidin in Gansu Provincial People's Hospital and reviewed the relevant literature. This patient, a 67-year-old man, was diagnosed multiple myeloma (IgA-κ, DS Ⅲ, ISS Ⅱ, R-ISS Ⅰ), after VRD induction and autologous stem cell transplantation, achieved complete remission and then lenalidomide maintenance therapy. In a state of continuous complete remission, the patient developed acute myeloid leukemia (high-risk group) 4 years and 4 months after diagnosis, then given venetolclax combined with azacidacidin. After the first course of treatment, the patient had complete morphologic remission of acute myeloid leukemia, MRD was negative, and the clinical symptoms improved significantly. After a total of 3 courses of the same treatment, the myeloid morphology of acute myeloid leukemia persisted in remission, but the proportion of abnormal plasma cells increased significantly, multiple myeloma recurred, and the patient abandoned treatment.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    MATEOS M V, CAVO M, BLADE J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (alcyone): a randomised, open label, phase 3 trial[J]. Lancet, 2020, 395(10218): 132-141.
    [2]
    SAMRA B, RICHARD-CARPENTIER G, KADIA T M, et al. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype[J]. Blood Cancer J, 2020, 10(5): 47. DOI: 10.1038/s41408-020-0316-3.
    [3]
    ESTEY E, KARP J E, EMADI A, et al. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?[J]. Leukemia, 2020, 34(3): 671-681.
    [4]
    HOWELL D, SMITH A, APPLETON S, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival-findings from a UK population-based study[J]. Brit J Haematol, 2017, 177(1): 67-71.
    [5]
    LAAKSO M, LAHTINEN R. Acute leukemia and the secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study[J]. Eur J Haematol, 2000, 65(2): 123-127.
    [6]
    JIA J, CHEN W M. Characterization and prognostic features of secondary acute myeloid leukemia in survivors of multiple myeloma[J]. Am J Cancer Res, 2023, 13(10): 4803-4810.
    [7]
    BACCHIARRI F, SAMMARTANO V, SANTONI A, et al. First reported case of secondary mixed phenotype acute leukemia after multiple myeloma[J]. Am J Blood Res, 2021, 11(1): 123-131.
    [8]
    JONES J R, CAIRNS D A, MENZIES T, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4 358 patients treated in the myeloma XI trial[J]. EClinical Medicine, 2023, 62: 102099. DOI: 10.1016/j.eclinm.2023.102099.
    [9]
    SALEEM K, FRANZ J, KLEM M L, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis[J]. Lancet Haematol, 2022, 9(12): e906-e918.
    [10]
    李玲玲, 李梦琳, 张雨, 等. 多发性骨髓瘤患者继发或伴发第二肿瘤的临床特征及预后转归分析[J]. 中国实验血液学杂志, 2023, 31(2): 429-434.

    LI L L, LI M L, ZHANG Y, et al. Clinical Features and Prognosis of Multiple Myeloma Patients with Secondary Primary Malignancies[J]. Journal of Experimental Hematology, 2023, 31(2): 429-434.
    [11]
    MUSTO P, ANDERSON K C, ATTAL M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus[J]. Ann Oncol, 2017, 28: 228-245.
    [12]
    ATTAL M, LAUWERS-CANCES V, MARIT G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366: 1782-1791.
    [13]
    ARBER D A, ORAZI A, HASSERJIAN R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
    [14]
    HULEGARDH E, NILSSON C, LAZAREVIC V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry[J]. Am J Hematol, 2015, 1: 208-214.
    [15]
    LI Z, LABOPIN M, CICERI F, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: acute leukemia working party (ALWP) of the European society for blood and marrow transplantation (EBMT) study[J]. Am J Hematol, 2018, 93(6): 769-777.
    [16]
    OTOUKESH S, SALMAN A, MARCUCCI G, et al. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies[J]. Leuk Res, 2019, 84: 106196. DOI: 10.1016/j.leukres.2019.106196.
    [17]
    魏小芳, 冯友繁, 丁国胜, 等. 维奈克拉联合阿扎胞苷治疗原发性骨髓纤维化转急性巨核细胞白血病1例并文献复习[J]. 中华全科医学, 2024, 22(3): 526-529. doi: 10.16766/j.cnki.issn.1674-4152.003441

    WEI X F, FENG Y F, DING G S, et al. Venetoclax combined with azacitidine in treatment of acute megakaryoblastic leukemia transformed from primary myelofibrosis: report of 1 case and review of literature[J]. Chinese Journal of General Practice, 2024, 22(3): 526-529. doi: 10.16766/j.cnki.issn.1674-4152.003441
    [18]
    孙立, 叶少杰, 周楠, 等. 维奈克拉联合阿扎胞苷治疗不适合标准化疗的新诊断急性髓系白血病疗效分析: 单中心数据[J]. 中华血液学杂志, 2022, 43(10): 826-832.

    SUN L, YE S J, ZHOU N, et al. Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience[J]. Chinese Journal of Hematology, 2022, 43(10): 826-832.
    [19]
    娄典, 刘利, 秦炜炜. 维奈克拉联合阿扎胞苷治疗老年初治急性髓系白血病的临床分析[J]. 中国肿瘤临床, 2022, 49(15): 775-780.

    LOU D, LIU L, QIN W W. Clinical analysis of venetoclax combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia[J]. Chinese Journal of Clinical Oncology, 2022, 49(15): 775-780.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (5) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return